CurrentPremera BluecrossPolicy 8.01.540

Cranial Electrotherapy Stimulation and Auricular Electrostimulation

Defines coverage stance and criteria for cranial electrotherapy stimulation (CES) and auricular electrostimulation (including auricular neurostimulation for opioid withdrawal) for Premera Bluecross members; includes coding, evidence review, regulatory clearance, and history.

Policy Summary

PayerPremera Bluecross

PolicyCranial Electrotherapy Stimulation and Auricular Electrostimulation

Policy CodePolicy 8.01.540

Change TypeRenumbered; coding updates

Effective DateMay 1, 2025

Next Review Date

Key ActionClaims for CES, auricular electrostimulation, and auricular neurostimulation for opioid withdrawal are investigational and may be denied as not medically necessary per this policy.

SourceLink

POLICY UPDATE CHANGES

Policy renumbered from 8.01.58 to 8.01.540; policy statements unchanged.

Added HCPCS codes A4543 and E0721 effective 10/01/2024.

Added CPT code 0783T (01/01/23).

Added HCPCS code E0732 (01/01/24).

3Procedures / Indications listed as investigational

~severalFDA-cleared devices listed

multipleRelated CPT/HCPCS codes

Coverage Summary & Stance

This policy covers cranial electrotherapy stimulation (CES) and auricular electrostimulation for Premera Blue Cross members. CES and auricular electrostimulation deliver low-intensity electrical pulses to the scalp, earlobes, mastoid processes, or ear acupuncture points to treat conditions such as depression, anxiety, insomnia, pain, obesity, and opioid withdrawal. Several devices for these technologies have received FDA 510(k) clearances for specific indications. However, published clinical evidence is limited and heterogeneous, and policy statements remain that these procedures are investigational.

Policy metadata

Policy number8.01.540

SubjectCranial Electrotherapy Stimulation and Auricular Electrostimulation

Effective date2025-05-01

Last review2025-04-07

StatusCURRENT

Coverage stanceInvestigational / Not covered

Stats - Procedures / Indications listed as investigational3

Stats - FDA-cleared devices listed~several

Stats - Related CPT/HCPCS codesmultiple

Provider Actions & Billing Impact

Denial Risk

Services considered investigational

Claims for cranial electrotherapy stimulation (CES), auricular electrostimulation, and auricular neurostimulation for opioid withdrawal are investigational and may be denied as not medically necessary per this policy.

0783T
A4543
A4596
E0721
E0732
S8930

Operationally, no prior authorization requirements are specified in this brief; however, services that are considered investigational may be denied as not medically necessary. Claims for CES, auricular electrostimulation, and auricular neurostimulation for opioid withdrawal may be denied, and providers should ensure documentation supports medical necessity if applicable.

Relevant CPT / HCPCS Codes

Coding - CPTCPT

0783T

Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.

Coding - HCPCSHCPCS

A4543	Supplies for transcutaneous electrical nerve stimulator; for nerves in the auricular region, per month (New code effective 10/1/2024).
A4596	Cranial electrotherapy stimulation (CES) system supplies and accessories, per month.
E0721	Transcutaneous electrical nerve stimulator for nerves in the auricular region (New code effective 10/1/2024).
E0732	Cranial electrotherapy stimulation (CES) system, any type.
S8930	Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with the patient.

No codes listed

Background & Evidence Summary

CES devices deliver weak pulses of electrical current to the earlobes, scalp, mastoid processes, or other cranial sites (eg, Alpha-Stim) and have been evaluated for insomnia, depression, anxiety, pain, and functional constipation. Auricular electrostimulation devices (eg, P-Stim, e-Pulse, Sparrow Ascent, NET Device) stimulate acupuncture points on the ear and have been studied for pain, weight loss, and opioid withdrawal.

Multiple devices for CES and auricular electrostimulation have received FDA 510(k) marketing clearance for specific indications (for example, Alpha-Stim and numerous CES devices cleared for insomnia, depression, and anxiety; several auricular devices cleared for practice of acupuncture or to reduce symptoms of opioid withdrawal). The clinical evidence consists mainly of small randomized trials, pooled analyses, and systematic reviews with inconsistent results and methodological limitations; overall the evidence is insufficient and heterogeneous to conclude these technologies improve net health outcomes.

Evidence Item	Summary
Systematic reviews / RCTs summary	Evidence is insufficient across indications to determine improvement in net health outcome; small RCTs and systematic reviews show inconsistent or marginal benefits with methodological limitations.
Ongoing trials	Multiple small ongoing trials (e.g., NCT06212609, NCT06203717) that may inform future reviews.

Cranial electrotherapy stimulation (CES): Delivery of weak pulses of electrical current to the earlobes, mastoid processes, or scalp via a device to modulate brain activity.

Auricular electrostimulation: Electrical stimulation of auricular acupuncture points using devices (eg, P-Stim) often worn behind the ear for several days.

Name	Number	Type	Effective date
No national coverage determination		NCD

Policy Revision History

01/01/23coding_added

Added CPT code 0783T (01/01/23).

01/01/24coding_added

Added HCPCS code E0732 (01/01/24).

10/01/24coding_added

Added HCPCS codes A4543 and E0721 effective 10/01/2024.

05/01/24renumbered

Policy renumbered from 8.01.58 to 8.01.540; policy statements unchanged. (Non-material change.)

05/01/25annual_reviewLatest

Annual Review (05/01/25): literature updated through 2025-01-07; policy statements unchanged. (Non-material change.)